Stoke Therapeutics, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-6.00
-88.00
-104.00
-101.00
-85.00
-52.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
16.00
-28.00
-6.00
43.00
0.00
2.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
45.00
-86.00
-81.00
-31.00
-66.00
-42.00
Cash Flow from Investing Activities
-186.00
-107.00
105.00
-45.00
-76.00
-1.00
Cash Flow from Financing Activities
97.00
131.00
53.00
46.00
1.00
108.00
Net Cash Inflow / Outflow
-43.00
-63.00
77.00
-31.00
-142.00
64.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Stoke Therapeutics, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-6.885
-165.673
159.00
95.84%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
16.346
47.097
-31.00
-65.29%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
45.585
-113.201
158.00
140.27%
Cash Flow from Investing Activities
-186.812
100.309
-286.00
-286.24%
Cash Flow from Financing Activities
97.389
65.086
32.00
49.63%
Net Cash Inflow / Outflow
-43.838
52.194
-95.00
-183.99%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is 152.49% vs -7.13% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
45.59
-86.85
152.49%






